Skip To Main Content
Pascal Turlure on Muck Rack

Pascal Turlure

As seen in: Nature, Wiley Online Library, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Pascal Turlure’s profile

Articles by Pascal Turlure

Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study

|
By Perrine Moyer, Thibaut Leguay, Maxime Jullien, Françoise Huguet, Amine Belhabri, Thomas Cluzeau, Ana Berceanu, Emmanuelle Tavernier, Karin Bilger, Pascal Turlure, Gabrielle Roth‐Guepin, Yosr Hicheri, Stéphane Leprêtre, Jean‐Noel Bastié
| Wiley Online Library Verified
Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study - Moyer - 2026 - Cancer - Wiley Online Library
Open in Who Shared Issue with article?

GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS

|
By Tereza Coman, Stephane Morisset, Raynier Devillier, Maud D’Aveni, Frédéric Baron, Jacques Olivier Bay, Jean El-Cheikh, Claude-Eric Bulabois, Cristina Castilla-Llorente, Patrice Ceballos, Yves Chalandon, Sylvain Chantepie, Magalie Joris, Patrice Chevallier, Mustafa Alani, Jérôme Cornillon, Edouard Forcade, Gaelle Guillerm, Helene Labussière, Philippe Lewalle, Johan Maertens, Florent Malard, Jean-Valère Malfuson, Natacha Maillard, Jean Baptiste Mear, Stéphanie Nguyen-Quoc, Xavier Poiré, Marie-Thérèse Rubio, Felipe Suarez, Pascal Turlure, Alban Villate, Ibrahim Yakoub-Agha, Nicole Raus, Marie Robin, Anne Huynh, Mauricette Michallet, Karine Bilger, Etienne Daguindeau, Chama Mokeddem, Mikael Loschi, Cécile Pivert
| Nature Verified
Abstract Post-transplant cyclophosphamide (PTCy) has transformed graft-versus-host disease (GVHD) prophylaxis but its role in matched-donor reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) remains uncertain.
Open in Who Shared Issue with article?

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort

|
By Lin Zhao, Céline Berthon, Laurène Fenwarth, Stephane de Botton, Thomas Cluzeau, Laure Farnault, Sylvain Chantepie, Pierre Arnautou, Thorsten Braun, Mathieu Leclerc, Delphine Lebon Verified, Juliette Lambert, Christophe Willekens, Emmanuel Raffoux, Ambroise Marçais, Pascal Turlure, Benjamin Carpentier, Madalina Uzunov, Reda Garidi, Alexandra Prado Coelho Verified, Karine Celli-Lebras, Raphael Itzykson, Claude Preudhomme, Nicolas Duployez, Hervé Dombret, Lionel Ades, Ahmad Aljijakli, Isabelle Plantier, Ollivier Legrand, Claire Bories, Emilie Lemasle, Kevin-James Wattebled, Celia Salanoubat, Jamile Frayfer, Iona Vaida, Renaud Buffet
| Nature Verified
Acute myeloid leukemia (AML) predominantly affects older adults, with two-thirds of cases diagnosed after the age of 60 [1]. In this population, therapeutic options have significantly expanded: intensive chemotherapy (ICT) remains the standard for fit patients, whereas venetoclax (Ven)–based low-intensity therapies (LIT) are increasingly used.
Open in Who Shared Issue with article?

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC

|
By Stephanie Nguyen, Patrice Ceballos, Edouard Forcade, Raynier Devillier, Aliénor Xhaard, Felipe Suarez, Karin Bilger, Anne Huynh, Hélène Labussiere-Wallet, Yves Beguin, Florence Beckerich, Pascal Turlure, Sylvain Chantepie, Claude-Eric Bulabois, Jean-Baptiste Mear, Cristina Castilla-Llorente, Mohamad Mohty Verified, Marie Robin, Xavier Poiré, Marie-Thérèse Rubio, Ana Berceanu, Ludovic Jondreville
| Nature Verified
The incidence rate of malignancies is increased in people living with HIV (PLWH) [1]. The first allogeneic hematopoietic stem cell transplantation (alloHSCT) in a human immunodeficiency virus (HIV)-seropositive recipient suffering from a hematological disorder was performed in 1989 [2], two years after zidovudine received approval for HIV treatment.
Open in Who Shared Issue with article?

Prognostic impact of intensive chemotherapy in patients with TP53- mutated AML

|
By Laurène Fenwarth, Loïc Vasseur, Nicolas Duployez, Augustin Boudry, Claude Gardin, Dominique Penther, Juliette Lambert, Stephane de Botton, Karine Celli-Lebras, Pascal Turlure, Thomas Cluzeau, Thorsten Braun, Maël Heiblig, Christian Récher, Sylvain Chantepie, Jean-Baptiste Micol, Cécile Pautas, Hervé Dombret, Claude Preudhomme, Raphael Itzykson
| Nature Verified
Acknowledgements The authors would like to thank all the investigators and clinical research associates from the ALFA-0701, ALFA-0702, and ALFA-1200 protocols. The authors thank Christophe Roumier for handling, conditioning, and storing patient samples (Tumour Bank for the Acute Leukemia French Association certification NF 96900-2014/65453-1, Centre Hospitalier Regional Universitaire Lille).
Open in Who Shared Issue with article?

Outcomes of mixed phenotype acute leukemia undergoing allogeneic stem cell transplantation: a retrospective study of the ALWP of EBMT

|
By Annalisa Paviglianiti, Maud Ngoya, Thomas Schroeder, Péter Reményi, Linde M. Morsink, Jaime Sanz, Ladislav Sopko, Francis Ayuk, Mareike Verbeek, Tessa Kerre, Matthias Eder, Pavel Zak, Pascal Turlure, Mieke Roeven, Alexander Kulagin, Alessandro Maggi Verified, Ron Ram, Alessandro Busca, Werner Rabitsch, Dominik Schneidawind, Eolia Brissot, Fabio Ciceri, Regis Peffault de la Tour, Mareike Durholt, Ibrahim Yakoubagha
| Nature Verified
Abstract Limited data is available on outcomes of mixed phenotype acute leukemia (MPAL) following allogeneic stem cell transplantation (HCT), and the impact of haploidentical HCT with post-transplant cyclophosphamide in this setting is lacking. We retrospectively analyzed 195 adults with MPAL undergoing HCT in first complete remission from 2014 to 2023. The 2-year overall survival (OS) and leukemia free survival (LFS) were 70.7% and 56.4%.
Open in Who Shared Issue with article?

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC

|
By Matthieu Jestin, Sébastien Maury, Anne Huynh, Edouard Forcade, Micha Srour, Cristina Castilla-Llorente, Jean-Baptiste Mear, Sylvain Chantepie, Dominik Schneidawind, Jakob Passweg, Claude-Eric Bulabois, Jérôme Cornillon, Michael Loschi, Jean-Valère Malfuson, Eolia Brissot, Pascal Turlure, Xavier Poiré, Carlos Graux, Nicole Raus, Alban Villate, Etienne Daguindau, Yves Chalandon, Gaelle Guillerm, Jacques-Olivier Bay, Clémence Loiseau, Natacha Maillard, Raynier Devillier, Marie-Thérèse Rubio, Franciane Paul, Sylvie François, Patrice Chevallier, Hélène Labussiere-Wallet, Hervé Dombret, Stephanie Nguyen, Nicolas Boissel, Nathalie Dhedin, Mustafa Alani, Véronique Lhéritier, Karin Bilger
| Nature Verified
In myeloablative HLA-matched hematopoietic stem cell transplantation (HSCT) peripheral blood stem cells (PBSC) increase the risk of chronic graft-versus-host disease (cGVHD) compared to bone marrow (BM) [1, 2]. While cGVHD is associated with substantial morbidity, it may also augment graft-versus-leukemia activity.
Open in Who Shared Issue with article?

Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure

|
By Johannes Clausen, Martin Carré, David Michonneau, Alexander Schauwvlieghe, Pedro Asensi Cantó, Sylvie François, Ludovic Gabellier, Lucía López Corral, Ana Benzaquén, Hélène Labussiere-Wallet, Jérôme Cornillon, Raynier Devillier, Anne Huynh, Pascal Turlure, Imi Faghmous, Florent Malard, Mohamad Mohty Verified, Cristina Castilla-Llorente, Anna Bauhofer, Hervé Jullien de Pommerol, Marion Bruelle, Behzad Kharabi Masouleh, Emilie Plantamura
| Nature Verified
Abstract CHRONOS is a multicenter, retrospective, cohort study involving acute graft-versus-host disease (aGvHD) adult patients with gastrointestinal (GI) symptoms, steroid- and ruxolitinib refractory, who initiated third-line therapy between 30 May 2019 and 30 September 2024. Primary endpoints were all-organ overall response rate (ORR) and GI-specific ORR (GI-ORR) around 28 days after treatment initiation.
Open in Who Shared Issue with article?

CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study

|
By Pierre Peterlin, Yannick Le Bris, Pascal Turlure, Audrey Ménard
| The Lancet Verified
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study - The Lancet Haematology
Open in Who Shared Issue with article?
Show More